Welcome to our dedicated page for Range Cancer Therapeutics ETF news (Ticker: CNCR), a resource for investors and traders seeking the latest updates and insights on Range Cancer Therapeutics ETF stock.
Range Cancer Therapeutics ETF (CNCR), advised by Exchange Traded Concepts, LLC, is a specialized exchange-traded fund focused on companies engaged in cancer research and treatments. The ETF provides investors with a diversified exposure to the leading companies in oncology, encompassing biopharmaceutical firms, medical device manufacturers, and healthcare service providers actively working on cancer therapies.
On October 23, 2023, CNCR underwent a significant transformation, absorbing the Loncar China BioPharma ETF (CHNA). This reorganization was executed after the close of business on October 20, 2023, allowing shareholders of CHNA to hold shares of CNCR at an equivalent net asset value (NAV). The transition resulted in CNCR issuing approximately 380,835.056 new shares, bringing its total assets to approximately $11,536,010 with an NAV per share of $9.77.
The reorganization was a taxable event, which means shareholders might recognize a gain or loss for federal income tax purposes, except for any gain or loss from the receipt of cash in lieu of fractional shares. Detailed information about this reorganization has been documented in the Information Statement/Prospectus filed with the SEC.
CNCR aims to capture value from the innovative and rapidly evolving field of cancer therapeutics by investing in companies at the forefront of developing breakthrough treatments. The fund is designed to provide a balanced portfolio that mitigates individual company risk while leveraging industry growth potential. As ETFs are traded on exchanges, CNCR shares can be bought and sold throughout the trading day at market prices, which may differ from their NAV.
Investors should consider the investment objectives, risks, charges, and expenses carefully before investing in CNCR. All investing involves risk, and the value of investments may fluctuate. A comprehensive understanding of these factors is essential, and this information is available in the CNCR ETF prospectus accessible via their website or by contacting the fund directly.
Exchange Traded Concepts, LLC, the investment advisor to CNCR, is known for managing thematic and innovative ETFs that provide unique market exposure. The fund is distributed by Quasar Distributors, LLC.
FAQ
What is the current stock price of Range Cancer Therapeutics ETF (CNCR)?
What is the Range Cancer Therapeutics ETF (CNCR)?
What was the recent reorganization involving CNCR?
How might the reorganization affect shareholders?
What types of companies does CNCR invest in?
Where can I find detailed information about CNCR?
What is the NAV per share of CNCR after the reorganization?
How does CNCR trade on the stock market?
Who manages CNCR?
What should investors consider before investing in CNCR?
How can I contact CNCR for more information?
